Published in Nat Med on March 13, 2005
The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol (2008) 6.82
Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol (2009) 5.65
Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron (2013) 3.63
Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet (2006) 3.23
Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A (2007) 3.07
Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci (2007) 3.02
Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest (2006) 3.00
Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther (2005) 2.47
Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol (2009) 2.19
Recent advances in lentiviral vector development and applications. Mol Ther (2010) 1.89
Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest (2009) 1.86
Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2007) 1.73
Potentiation of amyotrophic lateral sclerosis (ALS)-associated TDP-43 aggregation by the proteasome-targeting factor, ubiquilin 1. J Biol Chem (2008) 1.58
A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med (2006) 1.55
Modulating the expression of disease genes with RNA-based therapy. PLoS Genet (2007) 1.38
Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther (2013) 1.36
Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One (2008) 1.34
The involvement of microRNAs in neurodegenerative diseases. Front Cell Neurosci (2013) 1.30
Corticospinal motor neurons and related subcerebral projection neurons undergo early and specific neurodegeneration in hSOD1G⁹³A transgenic ALS mice. J Neurosci (2011) 1.29
Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res (2007) 1.20
Altered axonal architecture by removal of the heavily phosphorylated neurofilament tail domains strongly slows superoxide dismutase 1 mutant-mediated ALS. Proc Natl Acad Sci U S A (2005) 1.19
Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest (2006) 1.19
Decoding ALS: from genes to mechanism. Nature (2016) 1.18
Applications of lentiviral vectors for shRNA delivery and transgenesis. Curr Gene Ther (2008) 1.14
Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A (2014) 1.14
Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J Clin Invest (2011) 1.13
Human neural stem cell replacement therapy for amyotrophic lateral sclerosis by spinal transplantation. PLoS One (2012) 1.13
Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons. Mol Ther (2009) 1.13
RNAi: a potential new class of therapeutic for human genetic disease. Hum Genet (2011) 1.10
Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice. Mol Ther (2010) 1.07
Nonviral approaches for neuronal delivery of nucleic acids. Pharm Res (2007) 1.07
Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain (2013) 1.05
Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. Neurotherapeutics (2015) 1.05
Genetic therapy for the nervous system. Hum Mol Genet (2011) 1.03
Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet (2013) 1.02
Proteostasis and movement disorders: Parkinson's disease and amyotrophic lateral sclerosis. Cold Spring Harb Perspect Biol (2011) 1.02
Mice deficient in Cu,Zn-superoxide dismutase are resistant to acetaminophen toxicity. Biochem J (2006) 1.02
SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol (2013) 1.01
Rescue of pituitary function in a mouse model of isolated growth hormone deficiency type II by RNA interference. Endocrinology (2007) 0.97
ALS drug development: reflections from the past and a way forward. Neurotherapeutics (2008) 0.96
Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J Neurosci (2014) 0.95
Therapeutic regulation of gene expression in the inner ear using RNA interference. Adv Otorhinolaryngol (2009) 0.94
Efficient delivery of RNA Interference to peripheral neurons in vivo using herpes simplex virus. Nucleic Acids Res (2008) 0.93
Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies. RNA (2010) 0.92
Antioxidant gene therapy against neuronal cell death. Pharmacol Ther (2013) 0.92
Characterization of the Contribution of Genetic Background and Gender to Disease Progression in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis: A Meta-Analysis. J Neuromuscul Dis (2015) 0.92
Amyotrophic lateral sclerosis: update and new developments. Degener Neurol Neuromuscul Dis (2012) 0.91
Lentiviral delivery of RNAi for in vivo lineage-specific modulation of gene expression in mouse lung macrophages. Mol Ther (2013) 0.91
Peptide-modified vectors for nucleic acid delivery to neurons. J Control Release (2008) 0.90
Skeletal muscle in motor neuron diseases: therapeutic target and delivery route for potential treatments. Curr Drug Targets (2010) 0.89
Clinical applications involving CNS gene transfer. Adv Genet (2014) 0.89
Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice. Neurotherapeutics (2014) 0.89
Comparative analysis of HIV-1-based lentiviral vectors bearing lyssavirus glycoproteins for neuronal gene transfer. Genet Vaccines Ther (2009) 0.89
Retrogradely transported siRNA silences human mutant SOD1 in spinal cord motor neurons. Exp Brain Res (2009) 0.89
Genetic strategies to study TDP-43 in rodents and to develop preclinical therapeutics for amyotrophic lateral sclerosis. Eur J Neurosci (2011) 0.88
An animal model of oral dysphagia in amyotrophic lateral sclerosis. Dysphagia (2008) 0.88
Therapy development in spinal muscular atrophy. Nat Neurosci (2010) 0.88
Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi. PLoS One (2011) 0.87
Gene therapy in epilepsy. Epilepsia (2008) 0.87
A mouse model of pharyngeal dysphagia in amyotrophic lateral sclerosis. Dysphagia (2009) 0.87
SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice. Ann Clin Transl Neurol (2015) 0.86
Rabies virus envelope glycoprotein targets lentiviral vectors to the axonal retrograde pathway in motor neurons. J Biol Chem (2014) 0.86
Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy. Cell Mol Neurobiol (2006) 0.85
Specific retrograde transduction of spinal motor neurons using lentiviral vectors targeted to presynaptic NMJ receptors. Mol Ther (2014) 0.85
Aberrant neuregulin 1 signaling in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol (2012) 0.85
RNA interference in neuroscience: progress and challenges. Cell Mol Neurobiol (2005) 0.84
SOD1 aggregation in ALS mice shows simplistic test tube behavior. Proc Natl Acad Sci U S A (2015) 0.83
Mutant SOD1 knockdown in all cell types ameliorates disease in G85R SOD1 mice with a limited additional effect over knockdown restricted to motor neurons. J Neurochem (2010) 0.83
Enhanced neuronal Met signalling levels in ALS mice delay disease onset. Cell Death Dis (2011) 0.83
Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models. Neurosci Lett (2010) 0.83
Allele-specific knockdown of ALS-associated mutant TDP-43 in neural stem cells derived from induced pluripotent stem cells. PLoS One (2014) 0.82
Selection of RNAi-based inhibitors for anti-HIV gene therapy. World J Virol (2012) 0.81
Paradoxical Roles of Antioxidant Enzymes: Basic Mechanisms and Health Implications. Physiol Rev (2016) 0.81
Targeted delivery of siRNA. J Biomed Biotechnol (2006) 0.81
Specific Silencing of L392V PSEN1 Mutant Allele by RNA Interference. Int J Alzheimers Dis (2011) 0.81
Inhibitory RNA in epilepsy: research tools and therapeutic perspectives. Epilepsia (2010) 0.81
Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy. Cent Nerv Syst Agents Med Chem (2012) 0.81
Recent advances in RNA interference therapeutics for CNS diseases. Neurotherapeutics (2013) 0.81
Optimization of feline immunodeficiency virus vectors for RNA interference. J Virol (2006) 0.80
From animal models to human disease: a genetic approach for personalized medicine in ALS. Acta Neuropathol Commun (2016) 0.80
A high-throughput screen to identify inhibitors of SOD1 transcription. Front Biosci (Elite Ed) (2012) 0.80
Therapy for prion diseases: Insights from the use of RNA interference. Prion (2009) 0.80
Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates. Hum Gene Ther (2016) 0.79
The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy. BMC Cancer (2010) 0.79
Use of biomarkers in ALS drug development and clinical trials. Brain Res (2014) 0.79
Lentiviral vector-mediated RNA silencing in the central nervous system. Hum Gene Ther Methods (2013) 0.79
Nerve injection of viral vectors efficiently transfers transgenes into motor neurons and delivers RNAi therapy against ALS. Antioxid Redox Signal (2009) 0.79
Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol (2016) 0.78
Amyotrophic lateral sclerosis: applications of stem cells - an update. Stem Cells Cloning (2010) 0.78
Exploring the zebra finch Taeniopygia guttata as a novel animal model for the speech-language deficit of fragile X syndrome. Results Probl Cell Differ (2012) 0.78
Mouse neuronal cells expressing exogenous bovine PRNP and simultaneous downregulation of endogenous mouse PRNP using siRNAs. Prion (2010) 0.78
Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets? Neurodegener Dis Manag (2014) 0.78
Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis. Neurotherapeutics (2016) 0.78
PPARγ-coactivator-1α gene transfer reduces neuronal loss and amyloid-β generation by reducing β-secretase in an Alzheimer's disease model. Proc Natl Acad Sci U S A (2016) 0.78
Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J Neurol Neurosurg Psychiatry (2016) 0.78
Comparative analysis of lentiviral vectors and modular protein nanovectors for traumatic brain injury gene therapy. Mol Ther Methods Clin Dev (2014) 0.78
Heritable and inducible gene knockdown in astrocytes or neurons in vivo by a combined lentiviral and RNAi approach. Front Cell Neurosci (2014) 0.77
AAV6-mediated gene silencing fALS short. Mol Ther (2011) 0.77
Death Receptors in the Selective Degeneration of Motoneurons in Amyotrophic Lateral Sclerosis. J Neurodegener Dis (2013) 0.77
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 3.08
Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med (2004) 2.59
c-Jun reprograms Schwann cells of injured nerves to generate a repair cell essential for regeneration. Neuron (2012) 2.45
Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler (2010) 2.14
Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med (2010) 2.02
A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. J Cell Biol (2005) 2.01
Efficient production of germline transgenic chickens using lentiviral vectors. EMBO Rep (2004) 1.99
Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest (2004) 1.73
Deficits in axonal transport precede ALS symptoms in vivo. Proc Natl Acad Sci U S A (2010) 1.66
Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc Natl Acad Sci U S A (2010) 1.60
Induction of heat shock proteins for protection against oxidative stress. Adv Drug Deliv Rev (2009) 1.56
Mutations in BICD2 cause dominant congenital spinal muscular atrophy and hereditary spastic paraplegia. Am J Hum Genet (2013) 1.51
The distal hereditary motor neuropathies. J Neurol Neurosurg Psychiatry (2011) 1.46
Current developments in gene therapy for amyotrophic lateral sclerosis. Expert Opin Biol Ther (2015) 1.43
Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol (2012) 1.36
CAR-associated vesicular transport of an adenovirus in motor neuron axons. PLoS Pathog (2009) 1.35
Retinoic acid receptor beta2 promotes functional regeneration of sensory axons in the spinal cord. Nat Neurosci (2005) 1.31
Localised axial progenitor cell populations in the avian tail bud are not committed to a posterior Hox identity. Development (2008) 1.29
Optical control of muscle function by transplantation of stem cell-derived motor neurons in mice. Science (2014) 1.27
Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med (2009) 1.25
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res (2006) 1.24
Molecular landmarks along the axonal route: axonal transport in health and disease. Curr Opin Cell Biol (2008) 1.23
An ENU-induced mutation in mouse glycyl-tRNA synthetase (GARS) causes peripheral sensory and motor phenotypes creating a model of Charcot-Marie-Tooth type 2D peripheral neuropathy. Dis Model Mech (2009) 1.22
Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications. Hum Gene Ther (2006) 1.21
Rodent models of amyotrophic lateral sclerosis. Biochim Biophys Acta (2013) 1.17
The integration profile of EIAV-based vectors. Mol Ther (2006) 1.14
Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J Neurochem (2008) 1.13
Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol Ther (2004) 1.11
Retinoic acid receptor beta2 and neurite outgrowth in the adult mouse spinal cord in vitro. J Cell Sci (2002) 1.10
Interleukin 18 coexpression during respiratory syncytial virus infection results in enhanced disease mediated by natural killer cells. J Virol (2010) 1.09
Cytoplasmic dynein heavy chain: the servant of many masters. Trends Neurosci (2013) 1.09
A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer. Mol Cancer Ther (2009) 1.08
Axotomy-induced miR-21 promotes axon growth in adult dorsal root ganglion neurons. PLoS One (2011) 1.07
Efficient generation of transgenic pigs using equine infectious anaemia virus (EIAV) derived vector. FEBS Lett (2004) 1.07
MicroRNA-132 regulates recognition memory and synaptic plasticity in the perirhinal cortex. Eur J Neurosci (2012) 1.07
PTEN depletion rescues axonal growth defect and improves survival in SMN-deficient motor neurons. Hum Mol Genet (2010) 1.06
A comprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis. Dis Model Mech (2011) 1.05
Modification of superoxide dismutase 1 (SOD1) properties by a GFP tag--implications for research into amyotrophic lateral sclerosis (ALS). PLoS One (2010) 1.05
Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors. Methods Enzymol (2002) 1.04
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother (2008) 1.03
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res (2007) 1.02
A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament "hook" effect. J Neurosci Methods (2010) 1.01
Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Int Immunol (2008) 1.01
Optimised and rapid pre-clinical screening in the SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS). PLoS One (2011) 1.00
Phosphatase and tensin homologue/protein kinase B pathway linked to motor neuron survival in human superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain (2011) 1.00
Activation of protein kinase Czeta is essential for cytokine-induced metalloproteinase-1, -3, and -9 secretion from rabbit smooth muscle cells and inhibits proliferation. J Biol Chem (2002) 1.00
Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunol Immunother (2005) 0.99
A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease. Neurobiol Dis (2005) 0.99
Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection. J Virol (2010) 0.97
Chronic inhibition of endothelial nitric oxide synthase activity in nucleus tractus solitarii enhances baroreceptor reflex in conscious rats. J Physiol (2003) 0.97
Lentiviral vector expressing retinoic acid receptor beta2 promotes recovery of function after corticospinal tract injury in the adult rat spinal cord. Hum Mol Genet (2006) 0.96
Expression of mutant SOD1 in astrocytes induces functional deficits in motoneuron mitochondria. J Neurochem (2008) 0.96
Reversal of neurochemical changes and pain-related behavior in a model of neuropathic pain using modified lentiviral vectors expressing GDNF. Mol Ther (2006) 0.96
The SOD1 transgene in the G93A mouse model of amyotrophic lateral sclerosis lies on distal mouse chromosome 12. Amyotroph Lateral Scler Other Motor Neuron Disord (2005) 0.95
Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease. Invest Ophthalmol Vis Sci (2013) 0.95
Cortical overexpression of neuronal calcium sensor-1 induces functional plasticity in spinal cord following unilateral pyramidal tract injury in rat. PLoS Biol (2010) 0.95
Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model. Eur J Neurosci (2005) 0.95
Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J (2006) 0.94
Activation of the heat shock response in a primary cellular model of motoneuron neurodegeneration-evidence for neuroprotective and neurotoxic effects. Cell Mol Biol Lett (2009) 0.93
Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol Cancer Ther (2002) 0.93
Lentiviral-mediated delivery of Bcl-2 or GDNF protects against excitotoxicity in the rat hippocampus. Mol Ther (2005) 0.92
Local GDNF expression mediated by lentiviral vector protects facial nerve motoneurons but not spinal motoneurons in SOD1(G93A) transgenic mice. Neurobiol Dis (2004) 0.92
Amyotrophic lateral sclerosis: recent advances and future therapies. Curr Opin Neurol (2005) 0.91
Absence of disturbed axonal transport in spinal and bulbar muscular atrophy. Hum Mol Genet (2011) 0.91
Co-induction of the heat shock response ameliorates disease progression in a mouse model of human spinal and bulbar muscular atrophy: implications for therapy. Brain (2013) 0.91
New methods to titrate EIAV-based lentiviral vectors. Mol Ther (2002) 0.91